Pivotal Group, a Phoenix-based private investment firm, has acquired Precision Science, an animal health contract manufacturer specializing in pharmaceuticals, medicated feed additives and supplements, marking its first investment in the animal health industry.
The acquisition establishes a new animal health manufacturing platform for Pivotal Group, which plans to expand production capacity, invest in technology and strengthen Precision Science’s research and development capabilities.
Financial terms of the transaction were not disclosed.
Founded in 1989 and headquartered in Phoenix, Precision Science provides contract manufacturing and product development services to global animal health companies, supplement brands and other businesses serving the veterinary and animal care markets.
The company manufactures a range of animal health products, including pharmaceutical formulations, medicated feed additives and nutritional supplements.
Pivotal Group identified Precision Science as an opportunity to establish a larger manufacturing business within the growing animal health market, supported by the company’s established customer relationships and specialized production expertise.
“The acquisition of Precision Science represents an exciting opportunity for Pivotal Group to build a leading platform focused on animal health starting with supplements and pharmaceuticals,” said Francis Najafi, founder and chief executive officer of Pivotal Group.
Najafi said the investment firm plans to provide capital and operational resources to expand manufacturing capabilities, develop new technologies and support the company’s workforce.
Since completing the acquisition, Pivotal Group has invested additional capital into Precision Science to increase manufacturing capacity, upgrade technology and strengthen the infrastructure supporting its customers.
A central component of the expansion is a new 130,000-square-foot automated manufacturing facility under construction in North Phoenix.
The facility, which is approximately two-thirds complete, will significantly expand Precision Science’s production capabilities and provide additional capacity for future growth.
The new manufacturing site will add three production lines and enable the company to expand into liquid formulations, complementing its existing pharmaceutical and supplement manufacturing operations.
It will also increase analytical testing and product development capabilities while providing additional storage, logistics and distribution capacity.
The investment is intended to improve production efficiency and allow Precision Science to serve a broader range of animal health customers.
The new facility will operate alongside the company’s existing manufacturing infrastructure, creating additional opportunities to expand its product portfolio and contract manufacturing services.
Bryan Vincent, chief executive officer of Precision Science, said the acquisition will provide resources to support the company’s next phase of development.
“Our clients are asking us to look ahead—to anticipate where animal health is going and invest in the capabilities that will help them get there,” Vincent said.
He added that Pivotal Group’s investment will support workforce development, manufacturing expansion and additional product research capabilities.
Precision Science plans to maintain its focus on manufacturing quality, product safety and regulatory compliance as its operations expand.
The company operates an FDA-registered facility supported by an in-house laboratory and established quality management systems.
Its expanded manufacturing platform is expected to support additional hiring for production, technical and leadership positions in the Phoenix area.
The acquisition also represents a diversification of Pivotal Group’s investment portfolio into animal health and pharmaceutical contract manufacturing.
Founded by Francis Najafi, Pivotal Group focuses on acquiring and developing businesses with established market positions and opportunities for long-term growth.
The investment firm has previously backed technology businesses including Network Solutions, Global Capacity, Global Meet and MegaPath.
Pivotal Group also owns and operates Promontory, a luxury mountain community in Park City, Utah.
The Precision Science transaction provides Pivotal with an operating platform in the animal health sector, where contract manufacturers support pharmaceutical companies and supplement brands through specialized production and product development services.
The companies did not disclose the acquisition price, Precision Science’s annual revenue, its current employee count or the expected completion date of the new manufacturing facility.
The acquisition and ongoing facility expansion position Precision Science to increase its manufacturing capacity, introduce additional product capabilities and pursue growth opportunities across the animal health pharmaceuticals and supplements markets.


